Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Rodvold KA, George JM, Yoo L.

Clin Pharmacokinet. 2011 Oct;50(10):637-64. doi: 10.2165/11594090-000000000-00000. Review.

PMID:
21895037
2.

Penetration of vancomycin into epithelial lining fluid in healthy volunteers.

Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA.

Antimicrob Agents Chemother. 2011 Dec;55(12):5507-11. doi: 10.1128/AAC.00712-11. Epub 2011 Sep 12.

3.

Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.

Rodvold KA, Yoo L, George JM.

Clin Pharmacokinet. 2011 Nov 1;50(11):689-704. doi: 10.2165/11592900-000000000-00000. Review.

PMID:
21973267
4.

Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.

Lodise TP, Kinzig-Schippers M, Drusano GL, Loos U, Vogel F, Bulitta J, Hinder M, Sörgel F.

Antimicrob Agents Chemother. 2008 Jun;52(6):1945-51. Epub 2007 May 7.

5.

Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.

Lodise TP Jr, Gotfried M, Barriere S, Drusano GL.

Antimicrob Agents Chemother. 2008 Jul;52(7):2300-4. doi: 10.1128/AAC.01110-07. Epub 2008 Apr 21.

6.

Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs.

Hawkins EC, Boothe DM, Guinn A, Aucoin DP, Ngyuen J.

J Vet Pharmacol Ther. 1998 Feb;21(1):18-23.

PMID:
9507453
7.

Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections.

Togami K, Chono S, Morimoto K.

J Aerosol Med Pulm Drug Deliv. 2012 Apr;25(2):110-5. doi: 10.1089/jamp.2011.0894. Epub 2012 Feb 23.

PMID:
22360316
8.

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

Muller-Serieys C, Soler P, Cantalloube C, Lemaitre F, Gia HP, Brunner F, Andremont A.

Antimicrob Agents Chemother. 2001 Nov;45(11):3104-8.

9.

Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae.

Ong CT, Dandekar PK, Sutherland C, Nightingale CH, Nicolau DP.

Chemotherapy. 2005 Oct;51(6):339-46. Epub 2005 Oct 13.

PMID:
16224186
10.

Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes.

Schüler P, Zemper K, Borner K, Koeppe P, Schaberg T, Lode H.

Eur Respir J. 1997 May;10(5):1130-6.

11.

Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages.

Ikawa K, Kikuchi E, Kikuchi J, Nishimura M, Derendorf H, Morikawa N.

J Clin Pharm Ther. 2014 Aug;39(4):411-7. doi: 10.1111/jcpt.12157. Epub 2014 Mar 24.

PMID:
24661290
12.

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.

Wenzler E, Gotfried MH, Loutit JS, Durso S, Griffith DC, Dudley MN, Rodvold KA.

Antimicrob Agents Chemother. 2015 Dec;59(12):7232-9. doi: 10.1128/AAC.01713-15. Epub 2015 Sep 8.

13.

Delivering antibacterials to the lungs: considerations for optimizing outcomes.

Cazzola M, Blasi F, Terzano C, Matera MG, Marsico SA.

Am J Respir Med. 2002;1(4):261-72. Review.

PMID:
14720046
14.

Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.

Rodvold KA, Danziger LH, Gotfried MH.

Antimicrob Agents Chemother. 2003 Aug;47(8):2450-7.

15.

Distribution characteristics of orally administered olamufloxacin, a newly synthesized fluoroquinolone antibacterial, in lung epithelial lining fluid and alveolar macrophage in rats.

Sun J, Deguchi Y, Tauchi Y, He Z, Cheng G, Morimoto K.

Eur J Pharm Biopharm. 2006 Oct;64(2):238-45. Epub 2006 Jun 23.

PMID:
16875808
16.

Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.

Nicolau DP, Sutherland C, Winget D, Baughman RP.

Pulm Pharmacol Ther. 2012 Feb;25(1):94-8. doi: 10.1016/j.pupt.2011.12.007. Epub 2011 Dec 22.

PMID:
22210007
17.

Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.

Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2012 May;56(5):2627-34. doi: 10.1128/AAC.05354-11. Epub 2012 Feb 13.

18.

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel GJ, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL.

Antimicrob Agents Chemother. 2009 Aug;53(8):3294-301. doi: 10.1128/AAC.00144-09. Epub 2009 May 18.

19.

Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients.

Kuti JL, Nicolau DP.

Int J Antimicrob Agents. 2015 May;45(5):512-8. doi: 10.1016/j.ijantimicag.2014.12.028. Epub 2015 Feb 11.

PMID:
25726443
20.

Supplemental Content

Support Center